SCHEMBL2298515

SCHEMBL2298515

O=C1NCCN1c1ccc(S(=O)(=O)Oc2ccccc2Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGAV P06756 1/20 0.39
ITGA5 P08648 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB5 P18084 1/20 0.39
ITGB8 P26012 1/20 0.39
CMA1 P23946 2/20 0.37
HTR6 P50406 1/20 0.37
CYP1A1 P04798 3/20 0.37
EGFR P00533 1/20 0.37
ROS1 P08922 1/20 0.37
ALK Q9UM73 1/20 0.37
HTR2C P28335 4/20 0.36
KCNH2 Q12809 4/20 0.36
HTR2A P28223 1/20 0.36
SCN9A Q15858 1/20 0.36
MEN1 O00255 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2304331 0.85 L3MBTL1 (0.39) POLBL3MBTL1CMA1HTR2CSCN9A
SCHEMBL2303210 0.85 ALDH1A1 (0.48) L3MBTL1CMA1CYP1A1EGFRROS1
SCHEMBL12353646 0.85 LMNA (0.41) L3MBTL1CMA1HTR6SCN9AMEN1
SCHEMBL2305752 0.85 L3MBTL1 (0.39) POLBL3MBTL1HTR6CYP1A1SCN9A
SCHEMBL2301327 0.85 CYP1A1 (0.39) POLBITGB3ITGB1ITGAVITGA5
SCHEMBL2305423 0.82 KMT2A (0.42) L3MBTL1MEN1KMT2AMAPT
SCHEMBL14238623 0.82 L3MBTL1 (0.38) POLBL3MBTL1HTR6CYP1A1SCN9A
SCHEMBL2305210 0.82 DHODH (0.47) L3MBTL1CMA1HTR6CYP1A1MEN1
SCHEMBL2303163 0.81 SMN1; SMN2 (0.43) L3MBTL1CYP1A1MEN1KMT2ALMNA
SCHEMBL2303929 0.81 ALDH1A1 (0.48) CMA1HTR6CYP1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 POLB 3083/4885L3MBTL1 1374/4885ITGB3 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.